Nektar Therapeutics | NKTR - Selling And Administration Expenses


Nektar Therapeutics reported $10.17M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.58B 354M Mar/2026
Baxter International USD 728M 33M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Cipla INR 13.25B 101.8M Dec/2025
Dr.Reddys Laboratories INR 26.92B 482M Dec/2025
Eisai JPY 119.54B 7.82B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026